癌症药物反应的单细胞推断使用基于路径的变压器网络
Yinghao Yao1, Yuandong Xu1, Yaru Zhang1
1Oujiang Laboratory, Zhejiang Lab for Regenerative Medicine, Vision and Brain Health, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325101, China.
新的单细胞途径药物敏感性 (scPDS) 模型使用单细胞RNA测序数据准确预测癌症药物反应. 这种深度学习工具通过识别敏感细胞群体和预测治疗疗效来增强个性化治疗.
科学领域:
- 计算生物学是一种计算生物学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 准确预测癌症药物反应对于个性化医学至关重要.
- 单细胞RNA测序 (scRNA-seq) 揭示了细胞异质性和罕见的耐药群体.
- 大量和scRNA-seq之间的明显数据分布限制了来自大型细胞系数据集的知识传输.
研究的目的:
- 开发一种新的深度学习模型,scPDS,用于从scRNA-seq数据中预测药物敏感性.
- 为了克服散装和scRNA-seq之间的数据分布差异,以改善药物反应预测.
- 提高scRNA-seq分析在癌症药物反应预测中的准确性和效率.
主要方法:
- 开发了一个基于变压器的深度学习模型,单细胞途径药物敏感性 (scPDS).
- 采用途径激活转换来从scRNA-seq数据中预测药物敏感性.
- 从广泛的细胞系数据集中集成大量RNA-seq数据,以提高模型性能.
主要成果:
- 与最先进的方法相比,scPDS显示出更高的准确性和计算效率.
- 用博特佐米布治疗的乳腺癌细胞的分析揭示了药物耐药性的动态变化.
- 在耐药细胞中确定了对药物敏感的群体,并预测了组合疗法的有效性.
- 成功地区分了敏感和耐药患者,与生存结果相关联.
结论:
- scPDS提供了一个强大的计算工具,用于从scRNA-seq数据中预测细胞药物反应.
- 该模型为优化个性化癌症治疗策略提供了有价值的见解.
- scPDS有助于识别有效的药物组合和患者分层,以改善治疗结果.
更多相关视频
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Treatment Resistant Cancers
